Shaping genetic alterations in human cancer: the p53 mutation paradigm.
暂无分享,去创建一个
[1] L. Ellisen,et al. p63 and p73 in human cancer: defining the network , 2007, Oncogene.
[2] K. Sabapathy,et al. The codon 72 polymorphism-specific effects of human p53 are absent in mouse cells: implications on generation of mouse models , 2007, Oncogene.
[3] D. Sgroi,et al. The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers. , 2007, The Journal of clinical investigation.
[4] V. Rotter,et al. Transcription regulation by mutant p53 , 2007, Oncogene.
[5] A. Fersht,et al. Structure–function–rescue: the diverse nature of common p53 cancer mutants , 2007, Oncogene.
[6] T. Iwakuma,et al. Crippling p53 activities via knock-in mutations in mouse models , 2007, Oncogene.
[7] T. Soussi. p53 alterations in human cancer: more questions than answers , 2007, Oncogene.
[8] T. Stiewe,et al. The p53 family in differentiation and tumorigenesis , 2007, Nature Reviews Cancer.
[9] A. Levine,et al. A single nucleotide polymorphism in the p53 pathway interacts with gender, environmental stresses and tumor genetics to influence cancer in humans , 2007, Oncogene.
[10] T. Jacks,et al. Restoration of p53 function leads to tumour regression in vivo , 2007, Nature.
[11] Carlos Cordon-Cardo,et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas , 2007, Nature.
[12] J. Pietenpol,et al. Transcriptional Programs Regulated by p63 in Normal Epithelium and Tumors , 2007, Cell cycle.
[13] Michael A. Dyer,et al. MDMX: from bench to bedside , 2007, Journal of Cell Science.
[14] L. Vassilev,et al. MDM2 inhibitors for cancer therapy. , 2007, Trends in molecular medicine.
[15] Gerard I. Evan,et al. Modeling the Therapeutic Efficacy of p53 Restoration in Tumors , 2006, Cell.
[16] G. Wahl,et al. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas , 2006, Nature Reviews Cancer.
[17] G. Evan,et al. Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo. , 2006, Cancer cell.
[18] Michael A. Dyer,et al. Inactivation of the p53 pathway in retinoblastoma , 2006, Nature.
[19] Henning Tidow,et al. Effects of Oncogenic Mutations and DNA Response Elements on the Binding of p53 to p53-binding Protein 2 (53BP2)* , 2006, Journal of Biological Chemistry.
[20] M. Zvelebil,et al. iASPP preferentially binds p53 proline-rich region and modulates apoptotic function of codon 72–polymorphic p53 , 2006, Nature Genetics.
[21] C. Prives,et al. Mutant p53 gain of function: the NF-Y connection. , 2006, Cancer Cell.
[22] Julie E Goodman,et al. Association of breast cancer outcome with status of p53 and MDM2 SNP309. , 2006, Journal of the National Cancer Institute.
[23] S. Elledge,et al. ATM–Chk2–p53 activation prevents tumorigenesis at an expense of organ homeostasis upon Brca1 deficiency , 2006, The EMBO journal.
[24] A. Levine,et al. MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner. , 2006, Cancer research.
[25] G. Wahl,et al. A mouse p53 mutant lacking the proline-rich domain rescues Mdm4 deficiency and provides insight into the Mdm2-Mdm4-p53 regulatory network. , 2006, Cancer cell.
[26] K. Wiman,et al. Strategies for therapeutic targeting of the p53 pathway in cancer , 2006, Cell Death and Differentiation.
[27] M. Murphy,et al. Polymorphisms in the p53 pathway , 2006, Oncogene.
[28] O. Myklebost,et al. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[29] Wei Gu,et al. p53 ubiquitination: Mdm2 and beyond. , 2006, Molecular cell.
[30] Han You,et al. Coordination and communication between the p53 and IGF-1-AKT-TOR signal transduction pathways. , 2006, Genes & development.
[31] D. Menendez,et al. A SNP in the flt-1 promoter integrates the VEGF system into the p53 transcriptional network , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[32] B. Trink,et al. p63 and p73: teammates or adversaries? , 2006, Cancer cell.
[33] C. Ishioka,et al. Locus-specific mutation databases: pitfalls and good practice based on the p53 experience , 2006, Nature Reviews Cancer.
[34] P. Brennan,et al. Genetic polymorphisms in the base excision repair pathway and cancer risk: a HuGE review. , 2005, American journal of epidemiology.
[35] A. Levine,et al. Detection of functional single-nucleotide polymorphisms that affect apoptosis. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[36] T. Soussi. The p53 pathway and human cancer , 2005, The British journal of surgery.
[37] J. Manfredi,et al. The continuing saga of p53--more sleepless nights ahead. , 2005, Molecular cell.
[38] David P Lane,et al. p53 isoforms can regulate p53 transcriptional activity. , 2005, Genes & development.
[39] P. Hall,et al. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[40] W. Deppert,et al. A Novel Human p53 Isoform Is an Essential Element of the ATR-Intra-S Phase Checkpoint , 2005, Cell.
[41] Patrick Dumont,et al. The Codon 47 Polymorphism in p53 Is Functionally Significant*[boxs] , 2005, Journal of Biological Chemistry.
[42] T. Soussi,et al. p53 mutation heterogeneity in cancer. , 2005, Biochemical and biophysical research communications.
[43] Michelle R. Campbell,et al. Functionally distinct polymorphic sequences in the human genome that are targets for p53 transactivation. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[44] L. Strong,et al. Gain of Function of a p53 Hot Spot Mutation in a Mouse Model of Li-Fraumeni Syndrome , 2004, Cell.
[45] T. Jacks,et al. Mutant p53 Gain of Function in Two Mouse Models of Li-Fraumeni Syndrome , 2004, Cell.
[46] A. Levine,et al. A Single Nucleotide Polymorphism in the MDM2 Promoter Attenuates the p53 Tumor Suppressor Pathway and Accelerates Tumor Formation in Humans , 2004, Cell.
[47] M. Protopopova,et al. Small molecule RITA binds to p53, blocks p53–HDM-2 interaction and activates p53 function in tumors , 2004, Nature Medicine.
[48] T. Hubbard,et al. A census of human cancer genes , 2004, Nature Reviews Cancer.
[49] S. Kato,et al. Understanding the function–structure and function–mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[50] B. Gusterson,et al. p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. , 2003, Cancer cell.
[51] Petr Pancoska,et al. p53 has a direct apoptogenic role at the mitochondria. , 2003, Molecular cell.
[52] X. Wang,et al. TP53 and liver carcinogenesis , 2003, Human mutation.
[53] M. Murphy,et al. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential , 2003, Nature Genetics.
[54] M. Oren,et al. The p53-Mdm2 module and the ubiquitin system. , 2003, Seminars in cancer biology.
[55] J. Qin,et al. Parc A Cytoplasmic Anchor for p53 , 2003, Cell.
[56] Francesca Storici,et al. Differential Transactivation by the p53 Transcription Factor Is Highly Dependent on p53 Level and Promoter Target Sequence , 2002, Molecular and Cellular Biology.
[57] W. El-Deiry,et al. Tissue-specific induction of p53 targets in vivo. , 2002, Cancer research.
[58] Ting Wang,et al. Groups of p53 target genes involved in specific p53 downstream effects cluster into different classes of DNA binding sites , 2002, Oncogene.
[59] Ashok R Venkitaraman,et al. Cancer Susceptibility and the Functions of BRCA1 and BRCA2 , 2002, Cell.
[60] W. Mcdougal. An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma. , 2002, The Journal of urology.
[61] R. Ribeiro,et al. A novel mechanism of tumorigenesis involving pH-dependent destabilization of a mutant p53 tetramer , 2002, Nature Structural Biology.
[62] Yong Liao,et al. HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation , 2001, Nature Cell Biology.
[63] Xin Lu,et al. ASPP proteins specifically stimulate the apoptotic function of p53. , 2001, Molecular cell.
[64] R. Tibshirani,et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[65] L. Mayo,et al. A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[66] C. Prives,et al. A Subset of Tumor-Derived Mutant Forms of p53 Down-Regulate p63 and p73 through a Direct Interaction with the p53 Core Domain , 2001, Molecular and Cellular Biology.
[67] A. Yang,et al. p63 and p73: p53 mimics, menaces and more , 2000, Nature Reviews Molecular Cell Biology.
[68] A. Levine,et al. Physical and Functional Interaction between p53 Mutants and Different Isoforms of p73* , 2000, The Journal of Biological Chemistry.
[69] S. Hussain,et al. p53 Tumor Suppressor Gene: At the Crossroads of Molecular Carcinogenesis, Molecular Epidemiology, and Human Risk Assessment , 2000, Annals of the New York Academy of Sciences.
[70] B. Gusterson,et al. A common polymorphism acts as an intragenic modifier of mutant p53 behaviour , 2000, Nature Genetics.
[71] U. Moll,et al. Cytoplasmically “Sequestered” Wild Type p53 Protein Is Resistant to Mdm2-mediated Degradation* , 1999, The Journal of Biological Chemistry.
[72] Jijie Gu,et al. p73 is regulated by tyrosine kinase c-Abl in the apoptotic response to DNA damage , 1999, Nature.
[73] Reuven Agami,et al. Interaction of c-Abl and p73α and their collaboration to induce apoptosis , 1999, Nature.
[74] Antonio Costanzo,et al. The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage , 1999, Nature.
[75] B. Gusterson,et al. Novel p53 mutants selected in BRCA-associated tumours which dissociate transformation suppression from other wild-type p53 functions , 1999, Oncogene.
[76] C. Prives,et al. p73 Function Is Inhibited by Tumor-Derived p53 Mutants in Mammalian Cells , 1999, Molecular and Cellular Biology.
[77] R. Agami,et al. Interaction of c-Abl and p73alpha and their collaboration to induce apoptosis. , 1999, Nature.
[78] A. Riggs,et al. The p53 codon 249 mutational hotspot in hepatocellular carcinoma is not related to selective formation or persistence of aflatoxin B1 adducts , 1998, Oncogene.
[79] T. Soussi,et al. p53 mutations in BRCA1-associated familial breast cancer , 1998, The Lancet.
[80] L. Bracco,et al. The requirement for the p53 proline‐rich functional domain for mediation of apoptosis is correlated with specific PIG3 gene transactivation and with transcriptional repression , 1998, The EMBO journal.
[81] B. Gusterson,et al. p53 mutations in BRCA1-associated familial breast cancer , 1997, The Lancet.
[82] G. Prendergast,et al. The polyproline region of p53 is required to activate apoptosis but not growth arrest , 1997, Oncogene.
[83] P. Gruss,et al. Transgenic mouse model for studying the transcriptional activity of the p53 protein: age‐ and tissue‐dependent changes in radiation‐induced activation during embryogenesis , 1997, The EMBO journal.
[84] A. Levine,et al. Identification of a novel p53 functional domain that is necessary for efficient growth suppression. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[85] T. Iwama,et al. Molecular nature of colon tumors in hereditary nonpolyposis colon cancer, familial polyposis, and sporadic colon cancer. , 1996, Gastroenterology.
[86] U. Moll,et al. Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[87] D. Lane,et al. Coupling between gamma irradiation, p53 induction and the apoptotic response depends upon cell type in vivo. , 1995, Journal of cell science.
[88] R. Birgander,et al. Is p53 polymorphism maintained by natural selection? , 1994, Human heredity.
[89] F. Ponchel,et al. Hepatocarcinoma-specific mutant p53-249ser induces mitotic activity but has no effect on transforming growth factor beta 1-mediated apoptosis. , 1994, Cancer research.
[90] T. Jacks,et al. Sunburn and p53 in the onset of skin cancer , 1994, Nature.
[91] C. Harris,et al. Functional studies of a germ-line polymorphism at codon 47 within the p53 gene. , 1993, American journal of human genetics.
[92] J. Shay,et al. A transcriptionally active DNA-binding site for human p53 protein complexes , 1992, Molecular and cellular biology.
[93] K. Kinzler,et al. Definition of a consensus binding site for p53 , 1992, Nature Genetics.
[94] A. Puisieux,et al. Selective targeting of p53 gene mutational hotspots in human cancers by etiologically defined carcinogens. , 1991, Cancer research.
[95] V. Rotter,et al. Molecular basis for heterogeneity of the human p53 protein , 1986, Molecular and cellular biology.